SCHEMBL2699554

SCHEMBL2699554

N#CCc1cccc(N2CCC[C@@]3(CCN([C@H]4CC[C@H](O)CC4)C3=O)C2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 8/20 0.38
HCRTR2 O43614 5/20 0.35
HCRTR1 O43613 4/20 0.35
PRMT6 Q96LA8 1/20 0.34
OTUD7B Q6GQQ9 2/20 0.34
DPP4 P27487 1/20 0.34
MEN1 O00255 1/20 0.33
USP2 O75604 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
KMT2A Q03164 1/20 0.33
DRD2 P14416 1/20 0.33
DRD3 P35462 1/20 0.33
FLT3 P36888 1/20 0.33
TYRO3 Q06418 1/20 0.33
MERTK Q12866 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2699559 1.00 HSD11B1 (0.38) HSD11B1HCRTR2HCRTR1PRMT6OTUD7B
SCHEMBL549743 1.00 HSD11B1 (0.38) HSD11B1HCRTR2HCRTR1PRMT6OTUD7B
SCHEMBL551056 1.00 HSD11B1 (0.38) HSD11B1HCRTR2HCRTR1PRMT6OTUD7B
SCHEMBL549742 1.00 HSD11B1 (0.38) HSD11B1HCRTR2HCRTR1PRMT6OTUD7B
SCHEMBL551055 1.00 HSD11B1 (0.38) HSD11B1HCRTR2HCRTR1PRMT6OTUD7B
SCHEMBL2702427 0.88 HSD11B1 (0.43) HSD11B1
SCHEMBL550851 0.88 HSD11B1 (0.43) HSD11B1
SCHEMBL550850 0.88 HSD11B1 (0.43) HSD11B1
SCHEMBL2702428 0.88 HSD11B1 (0.43) HSD11B1
SCHEMBL549793 0.85 NOTUM (0.43) HSD11B1HCRTR2HCRTR1DRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2450351-A1 Lactam compounds and their use as pharmaceuticals Incyte Corporation (US) 2012-05-09 EP claimed
US-20060116382-A1 Lactam compounds and their use as pharmaceuticals INCYTE CORPORATION 2006-06-01 US claimed
EP-1812005-B1 LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2015-09-16 EP disclosed
EP-1812005-B1 LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2015-09-16 EP disclosed
EP-2450351-A1 Lactam compounds and their use as pharmaceuticals Incyte Corporation (US) 2012-05-09 EP disclosed
US-20060116382-A1 Lactam compounds and their use as pharmaceuticals INCYTE CORPORATION 2006-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060116382-A1 Lactam compounds and their use as pharmaceuticals HSD11B1, HSD11B2, HSD17B1 HSD11B1 1/4885HCRTR2 3116/4885HCRTR1 2917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.